OPINION STATEMENT: Leber's hereditary optic neuropathy (LHON) is a maternally inherited blinding disease with variable penetrance. Three primary mitochondrial DNA mutations, affecting the respiratory complex I, are necessary but not sufficient to cause blindness. Reduced efficiency of ATP synthesis and increased oxidative stress are believed to sensitize the retinal ganglion cells to apoptosis. Different therapeutic strategies are considered to counteract this pathogenic mechanism. However, potential treatments for the visual loss are complicated by the fact that patients are unlikely to benefit after optic atrophy occurs. There is no proven therapy to prevent or reverse the optic neuropathy in LHON. Results from a recent trial with idebenone hold promise to limit neurodegeneration and improve final outcome, promoting recovery of visual acuity. Other therapeutic options are under scrutiny, including gene therapy, agents increasing mitochondrial biogenesis, and anti-apoptotic drugs.

Leber's Hereditary optic Neuropathy / Sadun A.A.; La Morgia C.; Carelli V.. - In: CURRENT TREATMENT OPTIONS IN NEUROLOGY. - ISSN 1092-8480. - ELETTRONICO. - 13:(2011), pp. 109-117. [10.1007/s11940-010-0100-y]

Leber's Hereditary optic Neuropathy

LA MORGIA, CHIARA;CARELLI, VALERIO
2011

Abstract

OPINION STATEMENT: Leber's hereditary optic neuropathy (LHON) is a maternally inherited blinding disease with variable penetrance. Three primary mitochondrial DNA mutations, affecting the respiratory complex I, are necessary but not sufficient to cause blindness. Reduced efficiency of ATP synthesis and increased oxidative stress are believed to sensitize the retinal ganglion cells to apoptosis. Different therapeutic strategies are considered to counteract this pathogenic mechanism. However, potential treatments for the visual loss are complicated by the fact that patients are unlikely to benefit after optic atrophy occurs. There is no proven therapy to prevent or reverse the optic neuropathy in LHON. Results from a recent trial with idebenone hold promise to limit neurodegeneration and improve final outcome, promoting recovery of visual acuity. Other therapeutic options are under scrutiny, including gene therapy, agents increasing mitochondrial biogenesis, and anti-apoptotic drugs.
2011
Leber's Hereditary optic Neuropathy / Sadun A.A.; La Morgia C.; Carelli V.. - In: CURRENT TREATMENT OPTIONS IN NEUROLOGY. - ISSN 1092-8480. - ELETTRONICO. - 13:(2011), pp. 109-117. [10.1007/s11940-010-0100-y]
Sadun A.A.; La Morgia C.; Carelli V.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/96733
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 47
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 92
social impact